MedTrace Logo

Evaluation of Coagulopathy in Critically Ill COVID-19 Patients.

NCT04479280 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 70

Last updated 2020-09-09

No results posted yet for this study

Summary

Novel coronavirus disease 19 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), this pneumonia was first emerged in December 2019 in Wuhan, China and rapidly spread around the world .

Coagulopathy is one of the most significant prognostic factors in patients with COVID-19 and is associated with increased mortality and admission to critical care. Most observed coagulopathy in patients hospitalized with COVID-19 (COVID-19-associated coagulopathy) is characterized by increased D-dimer and fibrinogen levels. 71% of patients who did not survive hospitalization reported to have developed disseminated intravascular coagulation

Conditions

  • Coagulation Disorder

Interventions

DEVICE

Sonclot Coagulation and platelet function Analyzer SCP1, Sienco, USA

studying coagulation disorders in COVID19 critically ill patients

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-20
Primary Completion
2020-08-16
Completion
2020-08-16
FDA Device
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04479280 on ClinicalTrials.gov